Adagene (ADAG) Expected to Announce Quarterly Earnings on Thursday

Adagene (NASDAQ:ADAGGet Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Adagene to post earnings of ($0.33) per share for the quarter.

Adagene Stock Performance

Shares of NASDAQ:ADAG opened at $1.77 on Tuesday. The firm has a 50 day moving average of $1.88 and a 200-day moving average of $2.19. Adagene has a 12 month low of $1.64 and a 12 month high of $3.58.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ADAG shares. HC Wainwright raised their target price on Adagene from $5.00 to $8.00 and gave the company a “buy” rating in a report on Monday, January 27th. Morgan Stanley lowered Adagene from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 31st.

View Our Latest Research Report on ADAG

About Adagene

(Get Free Report)

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.

Featured Stories

Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.